PRISM MarketView highlighted seven public companies developing mental health therapies, devices, and digital platforms during National Mental Health Awareness Month. Featured firms include Helus Pharma (HELP), GH Research (GHRS), AtaiBeckley (ATAI), Definium Therapeutics (DFTX), BrainsWay (BWAY), Neuronetics (STIM), and Talkspace (TALK), spanning psychedelic-derived treatments, TMS, and virtual care.
GH Research (GHRS) has initiated a $200 million at-the-market share offering with Stifel, Nicolaus & Company to sell ordinary shares, providing the company with flexible access to equity capital. This move is intended to bolster its balance sheet and fund ongoing operations, although it could lead to dilution for existing shareholders. The offering leverages existing registration statements for efficiency.
GH Research PLC has announced an "at-the-market" equity offering sales agreement with Stifel, Nicolaus & Company to sell up to $200 million of ordinary shares. This offering will be conducted under an existing Form F-3 shelf registration. The company filed a prospectus supplement and an Irish legal opinion to support these potential sales, incorporating the report into several registration statements.
